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Visceral fat accumulation plays an important role in increasing the morbidity and mortality rates, 
by increasing the risk of developing several metabolic disorders, such as type 2 diabetes, 
dyslipidemia, and hypertension.  New genetic loci that are associated with increased systolic 
and diastolic blood pressures have been identified by genome-wide association studies in 
Caucasian populations.  This study investigates whether single nucleotide polymorphisms 
(SNPs) that confer susceptibility to high blood pressure are also associated with visceral fat 
obesity.  We genotyped 1279 Japanese subjects (556 men and 723 women) who underwent 
computed tomography (CT) for measuring the visceral fat area (VFA) and subcutaneous fat area 
(SFA) at the following SNPs: FGF5 rs16998073, CACNB2 rs11014166, C10orf107 rs1530440, 
CYP17A1 rs1004467, NT5C2 rs11191548, PLEKHA7 rs381815, ATP2B1 rs2681472 and 
rs2681492, ARID3B rs6495112, CSK rs1378942, PLCD3 rs12946454,and ZNF652 rs16948048.  
In an additive model, risk alleles of the CYP17A1 rs1004467 and NT5C2 rs11191548 were 
found to be significantly associated with reduced SFA (P = 0.00011 and 0.0016, respectively).  
When the analysis was performed separately in men and women, significant associations of 
rs1004467 (additive model) and rs11191548 (recessive model) with reduced VFA (P = 0.0018 
and 0.0022, respectively) and SFA (P = 0.00039 and 0.00059, respectively) were observed in 
women, but not in men.  Our results suggest that polymorphisms in the CYP17A1 and NT5C2 
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genes influence a reduction in both visceral and subcutaneous fat mass in Japanese women. 
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Metabolic syndrome is a combination of multiple risk factors, including central obesity, 
impaired glucose tolerance, dyslipidemia, and hypertension, which increases cardiovascular 
disease morbidity and mortality.1  Several studies have indicated that the intra-abdominal 
adipose tissue plays a central role in metabolic syndrome, since the accumulated visceral 
adipose tissue leads to alterations in the plasma levels of adipocytokines, resulting in the 
development of dyslipidemia, hypertension, and insulin resistance.2, 3  Intra-abdominal fat 
accumulation (central adiposity) is determined by waist circumference, waist-hip ratio, 
biological impedance, or the visceral fat area (VFA) measured using computed tomography 
(CT).1, 4, 5  There is abundant evidence that body fat distribution is influenced by genetic loci.6-8  
Individual variation in waist-hip ratio is heritable, with heritability estimates ranging from 22% 
to 61%.  Recent genome-wide association studies (GWAS) showed that genetic loci were 
associated with waist circumference and waist-hip ratio in the Caucasian population.9, 10  We 
previously reported that the rs1558902 and rs1421085 genotypes of the fat mass- and 
obesity-associated gene (FTO) were significantly associated with VFA, as well as with the 
subcutaneous fat area (SFA) and body mass index (BMI) in the Japanese population.11 
Recent progress in GWAS has increased the number of known genetic susceptibility 
loci for obesity.12-16  We investigated the association between the single nucleotide 
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polymorphisms (SNPs) underlying susceptibility to obesity and fat distribution (as determined 
by CT), and found that rs7498665 in the SH2B adaptor protein 1 (SH2B1) gene was associated 
with VFA, uncovering the genetic background of central obesity.17 
GWAS, and meta-analysis of GWAS, have identified various disease-associated 
genetic variations.18  Hypertension is one of the risk factors of metabolic syndrome, and 
considerably related to central obesity.  Obesity-associated allele of rs1558902 and rs1421085 
in the FTO gene were associated with hypertension, but not that of rs7498665 in the SH2B1 
gene in the Japanese population.19  The genetic variations associated with hypertension have 
been identified by GWAS.20, 21  In this study, we investigate whether the recently reported 
hypertension-related loci are also associated with VFA, which is another important factor 
responsible for metabolic syndrome. 
 
MATERIALS AND METHODS 
Study subjects 
We enrolled 1279 Japanese subjects from outpatient clinics; these patients agreed to undergo CT 
testing (in the supine position) to determine VFA and SFA values at the umbilical level (L4–L5), 
as previously reported.17  Both VFA and SFA values were calculated using the FatScan 
software program (N2system, Osaka, Japan).22  The patients visited the hospitals to undergo 
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treatment for obesity and/or metabolic abnormalities such as hypertension, dyslipidemia, and 
type 2 diabetes.  Patients with secondary obesity and obesity-related hereditary disorders were 
excluded from this study.  Patients with disease (such as cancer, and renal, heart and hepatic 
failure), or under treatment (such as corticosteroid and chemotherapy) that strongly affects body 
weight, were also excluded.  Athletes were also excluded from this study.  Clinical data were 
recorded at the first visit to the hospital.  The clinical characteristics of the subjects are 
summarized in Table 1.  Metabolic syndrome and metabolic abnormalities were diagnosed 
according to the criteria released by the Japanese Committee for the Diagnostic Criteria of 
Metabolic Syndrome in April 2005.4, 5  Written informed consent was obtained from each 
subject, and the protocol was approved by the ethics committee of each institution and by that of 
Kyoto University. 
DNA extraction and SNP genotyping 
Genomic DNA was extracted from the blood samples collected from each subject using the 
Genomix kit (Talent Srl, Trieste, Italy).  We selected 12 SNPs that were previously identified 
as susceptibility loci for hypertension by GWAS in Caucasian populations,20, 21 and constructed 
Invader probes (Third Wave Technologies, Madison, WI, USA) for each.  The 12 selected 
SNPs were as follows: rs16998073 in the fibroblast growth factor 5 (FGF5) gene; rs11014166 
in the calcium channel, voltage-dependent, β-2 subunit (CACNB2) gene; rs1530440 in the 
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chromosome 10 open reading frame 107 (C10orf107) gene; rs1004467 in the cytochrome P450, 
family 17, subfamily A, polypeptide 1 (CYP17A1) gene; rs11191548 in the 5'-nucleotidase, 
cytosolic II (NT5C2) gene; rs381815 in the pleckstrin homology domain containing, family A 
member 7 (PLEKHA7) gene; rs2681472 and rs2681492 in the ATPase, Ca2+ transporting, 
plasma membrane 1 (ATP2B1) gene; rs6495112 in the AT-rich interactive domain 3B 
(BRIGHT-like) (ARID3B) gene; rs1378942 in the c-src tyrosine kinase (CSK) gene; rs12946454 
in the phospholipase C, delta 3 (PLCD3) gene; and rs16948048 in the zinc finger protein 652 
(ZNF652) gene.  The SNPs were genotyped using Invader assays, as previously described.23  
The success rate of these assays was >99.0%. 
Statistical analysis 
For the additive model, we coded the genotypes as 0, 1, or 2 depending on the number of copies 
of the risk alleles.  For the recessive model, homozygosity with the risk allele was coded as 1 
and the others were coded as 0.  Risk alleles refer to the hypertension-associated alleles, 
according to previous reports.20, 21  Multiple linear regression analyses were performed to test 
the independent effect of the risk alleles on BMI, VFA, and SFA, by taking into account the 
effects of other variables (i.e., age and gender) that were assumed to be independent of the effect 
of each SNP.  The values of BMI, VFA, and SFA were logarithmically transformed before 
performing the multiple linear regression analysis.  Differences in the quantities of 
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anthropometric parameters among the different genotypes were assessed by the analysis of 
covariance (ANCOVA), by taking into account the effects of other variables (i.e., age and/or 
institute).  Hardy–Weinberg equilibrium was assessed using the χ2-test.24  To test SNP × SNP 
epistasis, we used a linear regression model for each SNP1 and SNP2, and fit the model in the 
form of Y = β0 + β1 × SNP1 + β2 × SNP2 + β3 × SNP1 × SNP2 + β4 × age + β5 × gender.  
Although we collected the samples at the region of Hondo (Kanto, Kinki, Chugoku, and 
Kyushu; Supplementary Table 1), we performed Wright’s F-statistics25 to evaluate the difference 
in the population structures of our sample using randomly selected 31 SNPs.  We divided our 
samples into 2 groups (SFA >208 cm2 and ≤208 cm2).  Median of SFA (208 cm2) was used as a 
cut-off value.  The results indicated that the population structure of 2 groups were almost the 
same in view of a very small FST value between the both groups (mean FST = 0.00023).  
Statistical analysis was performed using R software (http://www.r-project.org/).  P values were 




The clinical characteristics and genotypes of the subjects are shown in Tables 1 and 2, 
respectively.  All the SNPs were in Hardy–Weinberg equilibrium, and the minor allele 
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frequencies did not diverge from those reported in the HapMap database.  The BMI, VFA, and 
SFA values for each SNP genotype are reported in Table 3.  Multiple linear regression analyses 
of the anthropometric parameters with respect to the 12 analyzed SNPs are shown in Table 4.  
The A-allele of rs1004467 in the CYP17A1 gene was significantly associated with reduced BMI 
(P = 0.0018).  The other SNPs were not significantly associated with BMI.  No SNP was 
significantly associated with VFA.  The A-allele of rs1004467 in the CYP17A1 and the T-allele 
of rs11191548 in the NT5C2 gene were significantly associated with reduced SFA.  These 
SNPs are in linkage disequilibrium (LD), as reported in the HapMap database (D′ = 0.98, r2 = 
0.71), and the A-allele of rs1004467 and T-allele of rs11191548 are reported to be risk alleles for 
increased blood pressure.20, 21 
BMI, VFA, and SFA are known to be affected by gender; therefore, we compared 
rs1004467 and rs11191548 alleles with anthropometric parameters (BMI, VFA, and SFA) in 
men and women independently (Table 5).  Association of both SNPs with VFA (P = 0.0018 
and P = 0.0043) and SFA (P = 0.00039 and P = 0.0021) in women were significant except the 
association of T-allele of rs11191548 with VFA.  The VFA and SFA values of the rs11191548 
genotype suggest that the recessive model would be the best-fitted model both in men and 
women.  By using the recessive model, results revealed significant associations of the 
rs11191548 genotype with VFA (P = 0.0022) and SFA in women (P = 0.00059).  These SNPs 
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did not show any association with VFA or SFA in men, suggesting that they exhibit sexual 
dimorphism, as has been suggested in a recent report.26  As both rs1004467 and rs11191548 
were associated with a reduction in both VFA and SFA, we examined the association of these 
SNPs with total fat area (TFA).  The SNPs were significantly associated with TFA (P = 
0.00012 at rs1004467, P = 0.00052 at rs11191548 in additive model) in women, but not in men, 
suggesting that risk allele for high blood pressure of these SNPs are associated with reduced 
adiposity in women.  The very small mean FST value (0.00023) indicated no population 
structure in our subjects.  Since we collected the samples from 9 institutes in 4 regions in Japan 
(Supplementary Table 1), we tested multiple linear regression analysis with age and institute as 
explanatory variables in men and women.  The very similar results were observed.  In 
additive model, significant associations of the rs1004467 and rs11191548 genotype with VFA (P 
= 0.0015 and 0.0011, respectively) and SFA (P = 0.00021 and 0.00062, respectively) were 
observed in women (Supplementary Table 2).  Statistical analysis using ANCOVA indicated 
significant associations of the rs1004467 and rs11191548 genotype with VFA (P = 0.0020 and 
0.0015, respectively) and SFA (P = 0.00033 and 0.00042, respectively) in women 
(Supplementary Table 2).  Since some diabetes medications effect on adiposity,27 we 
performed the analysis excluding 147 type 2 diabetic patients treated with sulfonylureas, 
biguanides and thiazolidinediones  We found that the similar significant associations of the 
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rs1004467 and rs11191548 genotype with VFA and SFA in women (Supplementary Table 3).   
 We have reported that rs1558902 in the FTO gene is associated with both VFA and 
SFA,11 and that rs7498665 in the SH2B1 gene is associated with VFA.17  Thus, we examined 
SNP × SNP epistasis in men, women, and all subjects.  The combination of rs1004467 and 
rs7498665 exhibited no epistatic effect on VFA in men (P = 0.43), women (P = 0.86), or all 
subjects (P = 0.76).  The combination of rs1004467 and rs1558902 did not show epistatic 
effect on VFA in men (P = 0.99), women (P = 0.53), or all subjects (P = 0.60), or on SFA in 
men (P = 0.63), women (P = 0.83), or all subjects (P = 0.89). 
 Among the SNPs tested in this study, rs16998073 in the FGF5 gene and rs11191548 in 
the NT5C2 gene were associated with increased systolic blood pressure (P <0.05).  
Rs11191548 in the NT5C2 gene were also associated with hypertension (P <0.05).  We could 
replicate the association between blood pressure and the above 2 SNPs that were reported to be 
strongly associated with blood pressure in the Japanese population (Supplementary Table 4).28 
 
DISCUSSION 
In this study, we showed that the A-allele of rs1004467 in the CYP17A1 and the T-allele of 
rs11191548 in the NT5C2 gene were significantly associated with reduced VFA, SFA, and TFA 
in women.  Association of T-allele of rs11191548 in the NT5C2 gene with increased systolic 
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blood pressure and hypertension was replicated in our sample, as reported previously.28  Our 
hypothesis was that these risk alleles would be associated with increased VFA and/or SFA since 
increased adiposity is a risk for hypertension;4,5 however, these alleles affected decreased 
adiposity.  The associations between SNPs and increased blood pressure/hypertension were 
evaluated after adjusted for BMI, age and gender.  Thus, the SNPs associated with visceral fat 
obesity related and gender dependent hypertension would be excluded in the screening stage.  
Indeed, recent analysis has shown that genetic variation near insulin receptor substrate 1 (IRS1) 
is associated with reduced adiposity and an impaired metabolic profile.29  Thus, it is likely that 
rs1004467 and rs11191548 are associated with reduced VFA and SFA, as well as with 
hypertension in women. 
 The SNPs rs1004467 and rs11191548 were not associated with BMI in men or women, 
as reported for rs2943650 near IRS1.29  Since BMI represents both fat and lean body mass, our 
observation suggests that these SNPs influence a reduction in VFA and SFA, or influence an 
increased percentage of lean body mass.  The significant associations of rs1004467 and 
rs1191548 with reduced VFA and SFA were observed in women, but not in men.  The 
rs1004467 SNP located in the intron of the CYP17A1 gene.  CYP17A1 is involved in the 
biosynthesis of glucocorticoids, mineral corticoids, androgens, and estrogens.30  The 
rs1004467 risk allele may reflect differences in CYP17A1 gene expression that alter the 
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biosynthesis of steroid hormones, leading to hypertension and reduced adiposity in women.  
The region of LD that includes rs1004467 and rs11191548 contains a couple of genes in 
addition to CYP17A1: NT5C2, arsenic (+3 oxidation state) methyltransferase (AS3MT) and 
cyclin M2 (CNNM2).  NT5C2 is a cytosolic IMP/GMP selective 5′-nucleotidase and involved 
in nucleic acids or DNA synthesis.31  CNNM2 (ancient conserved domain protein, ACDP2) is a 
transporter of magnesium which is required for the catalytic activity of numerous 
metalloenzymes.32  Thus, these genes would be important for metabolism in adipocyte 
hyperplasia and hypertrophy.  Further investigation is warranted to elucidate the functional 
SNPs and susceptibility genes. 
 We have previously reported that FTO rs1558902 is associated with VFA and SFA, 
and that SH2B1 rs7498665 is associated with VFA.11, 17  Epistasis, or gene–gene interaction, 
has recently received much attention in human genetics.33  In this study, the effect of these 
SNPs on VFA and SFA was additive, and an epistatic effect was not observed. 
 In summary, we showed that CYP17A1 rs1004467 and NT5C2 rs11191548 SNPs are 
significantly associated with both reduced VFA and SFA in women.  Our results suggest that 
the region encompassing CYP17A1 to NT5C2 plays a role in reducing visceral and subcutaneous 
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Table 1  Clinical characteristics of the subjects 
 Men Women Total 
n 556 723 1279 
Age (years) 49.4 ± 12.2 52.2 ± 11.3 51.0 ± 11.8 
BMI (kg m-2) 30.2 ± 6.1 28.1 ± 5.3 29.0 ± 5.8 
VFA (cm2) 155.3 ± 67.7 99.8 ± 53.6 123.9 ± 66.1 
SFA (cm2) 206.7 ± 108.6 241.6 ± 97.2 226.5 ± 103.7 
Waist circumference (cm) 97.5 ± 11.3 91.8 ± 10.3 94.2 ± 11.1 
    
Prevalence of metabolic disease    
  Dyslipidemia 293 (53%) 244 (34%) 537 (42%) 
  Hypertension 379 (68%) 452 (63%) 831 (65%) 
  Impaired fasting glucose 177 (32%) 176 (24%) 353 (28%) 
  Metabolic syndrome 248 (45%) 162 (22%) 410 (32%) 
Data are represented as mean ± SD. 
Table 2  Genotypic characteristics of the subjects 












rs16998073 4 81,403,365 FGF5 T/A T 120/514/644 0.24 
rs11014166 10 18,748,804 CACNB2 T/A A 4/124/1151 0.73 
rs1530440 10 63,194,597 C10orf107 T/C C 30/296/953 0.22 
rs1004467 10 104,584,497 CYP17A1 A/G A 559/567/153 0.62 
rs11191548 10 104,836,168 NT5C2 T/C T 675/504/100 0.66 
rs381815 11 16,858,844 PLEKHA7 C/T T 842/381/56 0.13 
rs2681472 12 88,533,090 ATP2B1 A/G A 546/562/171 0.17 
rs2681492 12 88,537,220 ATP2B1 C/T T 168/561/549 0.19 
rs6495112 15 72,619,851 ARID3B A/C A 530/575/173 0.39 
rs1378942 15 72,864,420 CSK A/C C 49/410/817 0.78 
rs12946454 17 40,563,647 PLCD3 T/A T 34/343/901 0.84 
rs16948048 17 44,795,465 ZNF652 G/A G 18/326/935 0.08 
BP, blood pressure; CHR, chromosome; HWE, Hardy–Weinberg equilibrium. 
Table 3  Mean BMI, VFA, and SFA for 12 blood pressure risk variants 
   Mean ± SD  
  BMI (kg m-2)  VFA (cm2)  SFA (cm2) 
 Nearby  Genotype   Genotype   Genotype  
SNP ID Gene 11 12 22 11 12 22 11 12 22 
rs16998073 FGF5 28.8 ± 4.7 29.0 ± 5.8 29.0 ± 6.0 126.2 ± 66.1 121.6 ± 66.5 125.3 ± 65.9 227.4 ± 98.3 224.5 ± 111.0 227.7 ± 98.7 
rs11014166 CACNB2 27.0 ± 2.7 29.6 ± 6.1 28.9 ± 5.8 123.4 ± 82.2 136.7 ± 68.2 122.5 ± 65.8 178.6 ± 35.8 233.7 ± 106.4 225.8 ± 103.6 
rs1530440 C10orf107 30.8 ± 6.5 28.6 ± 5.4 29.1 ± 5.9 129.8 ± 63.1 120.2 ± 66.4 124.9 ± 66.2 236.4 ± 119.2 223.0 ± 91.4 227.2 ± 106.9 
rs1004467 CYP17A1 28.4 ± 5.6 29.5 ± 6.1 29.4 ± 5.2 117.5 ± 64.9 130.6 ± 68.5 122.5 ± 59.3 215.5 ± 92.7 231.4 ± 111.5 247.9 ± 107.9 
rs11191548 NT5C2 28.6 ± 5.8 29.5 ± 5.9 28.9 ± 5.1 119.2 ± 65.3 130.9 ± 68.6 120.5 ± 55.7 217.2 ± 96.0 238.5 ± 113.2 228.1 ± 98.8 
rs381815 PLEKHA7 29.2 ± 5.9 28.7 ± 5.7 27.8 ± 4.3 124.1 ± 64.2 124.3 ± 71.5 117.9 ± 55.9 229.4 ± 105.9 221.5 ± 101.6 215.3 ± 83.1 
rs2681472 ATP2B1 29.2 ± 5.8 28.8 ± 5.4 29.0 ± 7.0 127.1 ± 67.5 121.5 ± 64.8 121.8 ± 65.8 227.4 ± 100.4 223.5 ± 100.3 233.1 ± 123.6 
rs2681492 ATP2B1 29.0 ± 7.1 28.7 ± 5.2 29.3 ± 5.9 121.9 ± 66.3 121.4 ± 64.8 127.0 ± 67.4 234.6 ± 123.9 221.9 ± 98.3 228.7 ± 102.3 
rs6495112 ARID3B 28.9 ± 5.8 29.0 ± 5.7 29.3 ± 6.2 122.5 ± 63.4 125.0 ± 69.2 124.9 ± 64.3 223.7 ± 106.5 229.5 ± 102.6 225.1 ± 99.2 
rs1378942 CSK 28.0 ± 4.2 28.9 ± 6.1 29.1 ± 5.7 110.0 ± 63.3 121.8 ± 62.4 125.6 ± 67.6 222.9 ± 84.5 225.9 ± 104.3 227.0 ± 104.7 
rs12946454 PLCD3 30.1 ± 8.2 28.6 ± 5.0 29.1 ± 5.9 137.2 ± 80.0 123.0 ± 67.4 123.7 ± 65.1 254.4 ± 105.0 216.4 ± 93.7 229.2 ± 107.0 
rs16948048 ZNF652 28.1 ± 2.8 29.4 ± 5.9 28.9 ± 5.8 128.6 ± 73.7 124.8 ± 65.9 123.5 ± 66.1 215.0 ± 60.6 227.0 ± 96.3 226.5 ± 106.9 
11, allele1/allele1; 12, allele1/allele2; 22, allele2/allele2.  Allele 1 and allele 2 of each SNP is indicated in Table 2. 
Table 4  Relationship between blood pressure-associated loci and adiposity measures 
 Nearby BMI VFA SFA 
SNP ID gene β SE P-value β SE P-value β SE P-value 
rs16998073 FGF5 -0.002 0.003 0.55 -0.003 0.010 0.78 -0.010 0.008 0.22 
rs11014166 CACNB2 -0.005 0.007 0.48 -0.043 0.021 0.043 -0.008 0.017 0.63 
rs1530440 C10orf107 -0.002 0.004 0.71 0.010 0.014 0.48 -0.005 0.011 0.64 
rs1004467 CYP17A1 -0.010 0.003 0.0018 -0.022 0.010 0.027 -0.030 0.008 0.00011 
rs11191548 NT5C2 -0.008 0.003 0.015 -0.019 0.011 0.078 -0.026 0.008 0.0016 
rs381815 PLEKHA7 -0.007 0.004 0.046 -0.004 0.012 0.76 -0.015 0.009 0.10 
rs2681472 ATP2B1 0.002 0.003 0.43 0.006 0.010 0.52 0.005 0.008 0.49 
rs2681492 ATP2B1 0.003 0.003 0.34 0.006 0.010 0.54 0.006 0.008 0.40 
rs6495112 ARID3B -0.002 0.003 0.45 -0.004 0.010 0.65 -0.007 0.008 0.36 
rs1378942 CSK 0.005 0.004 0.20 0.010 0.012 0.40 0.005 0.009 0.61 
rs12946454 PLCD3 -0.003 0.004 0.39 0.009 0.013 0.50 -0.011 0.010 0.28 
rs16948048 ZNF652 0.005 0.004 0.30 0.008 0.014 0.57 0.005 0.011 0.67 
Data were derived from a linear regression analysis.  The values of BMI, VFA, and SFA were logarithmically transformed.  Logarithmically 
transformed BMI, VFA, and SFA were adjusted for age and gender.  Tested alleles are risk alleles of increased blood pressure. 
Table 5  Relationship between rs1004467 and rs11191548, and adiposity in men and women 
SNP ID   Values at each genotype Additive model Recessive model 
(gene) Phenotype Gender 11 12 22 β (SE) P-value β (SE) P-value 
rs1004467 n Men 233 259 64     
(CYP17A1)  Women 326 308 89     
 BMI (kg m-2) Men 29.7 ± 6.6 30.6 ± 5.9 30.1 ± 5.1 -0.011 (0.005) 0.029 -0.017 (0.006) 0.0085 
  Women 27.6 ± 4.6 28.5 ± 6.0 28.9 ± 5.3 -0.010 (0.004) 0..017 -0.013 (0.006) 0.019 
 VFA (cm2) Men 152.9 ± 67.7 160.6 ± 69.2 142.8 ± 59.9 0.004 (0.014) 0.78 -0.012 (0.019) 0.52 
  Women 92.3 ± 49.2 105.4 ± 56.8 107.8 ± 54.7 -0.044 (0.014) 0.0018 -0.061 (0.019) 0.0014 
 SFA (cm2) Men 198.6 ± 103.0 211.9 ± 113.8 215.4 ± 106.7 -0.028 (0.013) 0.037 -0.036 (0.018) 0.047 
  Women 227.6 ± 82.7 248.0 ± 106.9 271.2 ± 103.3 -0.033 (0.009) 0.00039 -0.040 (0.013) 0.0020 
rs11191548 n Men 289 220 47     
(NT5C2)  Women 386 284 53     
 BMI (kg m-2) Men 30.0 ± 6.8 30.6 ± 5.4 29.4 ± 5.4 -0.007 (0.005) 0.19 -0.013 (0.006) 0.049 
  Women 27.6 ± 4.7 28.7 ± 6.1 28.5 ± 4.8 -0.010 (0.004) 0.021 -0.015 (0.006) 0.0080 
 VFA (cm2) Men 153.8 ± 68.0 161.3 ± 69.3 137.2 ± 54.8 0.007 (0.014) 0.65 -0.008 (0.018) 0.65 
  Women 93.3 ± 49.3 107.4 ± 58.1 105.8 ± 52.8 -0.043 (0.015) 0.0043 -0.059 (0.019) 0.0022 
 SFA (cm2) Men 202.1 ± 107.5 214.3 ± 111.3 199.9 ± 102.5 -0.023 (0.014) 0.10 -0.035 (0.018) 0.048 
  Women 228.5 ± 84.9 257.4 ± 111.1 253.0 ± 89.0 -0.031 (0.010) 0.0021 -0.044 (0.013) 0.00059 
Values are shown as the mean ± SD.  Data were derived from a linear regression analysis.  The values of BMI, VFA, and SFA were logarithmically 
transformed.  Logarithmically transformed BMI, VFA, and SFA were adjusted for age.  Tested alleles (allele1 at both SNPs) are risk alleles of increased 
blood pressure. 
Supplementary Table 1  Clinical characteristics of the subjects in 4 regions 
 Regions 
 Kanto Kansai Chugoku Kyushu 
Number of institutes 3 2 2 1 
n 1080 126 64 9 
Men/Women 463/617 62/64 31/33 0/9 
Age (years) 51.1 ± 11.1 50.0 ± 14.2 51.4 ± 15.1 41.9 ± 17.5 
BMI (kg m-2) 28.0 ± 4.8 35.9 ± 7.1 30.7 ± 5.6 41.8 ± 8.1 
VFA (cm2) 118.2 ± 64.2 165.6 ± 68.4 129.8 ± 60.9 187.3 ± 61.5 
SFA (cm2) 215.1 ± 90.7 322.0 ± 134.8 204.3 ± 105.1 474.9 ± 158.2 
     
Genotype     
rs16998073 102/427/551 12/53/60 5/31/28 1/3/5 
rs11014166 4/101/975 0/14/112 0/8/56 0/1/8 
rs1530440 25/246/809 3/33/90 1/17/46 1/0/8 
rs1004467 481/463/136 50/63/13 27/34/3 1/7/1 
rs11191548 568/422/90 63/56/7 42/20/2 2/6/1 
rs381815 700/332/48 93/29/4 42/18/4 7/2/0 
rs2681472 467/471/142 55/55/16 21/30/13 3/6/0 
rs2681492 139/471/469 16/55/55 13/29/22 0/6/3 
rs6495112 447/490/142 50/58/18 29/23/12 4/4/1 
rs1378942 45/335/698 3/47/75 1/27/36 0/1/8 
rs12946454 26/291/763 2/34/89 4/17/43 2/1/6 
rs16948048 16/262/802 2/36/88 0/27/37 0/1/8 
Data are represented as mean ± SD. 
Supplementary Table 2  Relationship between rs1004467 and rs11191548, and adiposity in men and women adjusted for age and institute 
SNP ID   Values at each genotype ANCOVA P-value Additive model Recessive model 




age and institute 
β (SE) P-value β (SE) P-value 
rs1004467 n Men 233 259 64 – –     
(CYP17A1)  Women 326 308 89 – –     
 BMI  Men 29.7 ± 6.6 30.6 ± 5.9 30.1 ± 5.1 0.082 0.23 -0.009 (0.004) 0.044 -0.013 (0.006) 0.028 
 (kg m-2) Women 27.6 ± 4.6 28.5 ± 6.0 28.9 ± 5.3 0.033 0.015 -0.009 (0.003) 0.0049 -0.011 (0.005) 0.016 
 VFA Men 152.9 ± 67.7 160.6 ± 69.2 142.8 ± 59.9 0.13 0.13 0.007 (0.013) 0.59 -0.007 (0.018) 0.69 
 (cm2) Women 92.3 ± 49.2 105.4 ± 56.8 107.8 ± 54.7 0.0020 0.0026 -0.042 (0.013) 0.0015 -0.054 (0.018) 0.0029 
 SFA Men 198.6 ± 103.0 211.9 ± 113.8 215.4 ± 106.7 0.10 0.21 -0.024 (0.013) 0.066 -0.027 (0.017) 0.12 
 (cm2) Women 227.6 ± 82.7 248.0 ± 106.9 271.2 ± 103.3 0.00033 0.00013 -0.032 (0.009) 0.00021 -0.036 (0.012) 0.0027 
rs11191548 n Men 289 220 47       
(NT5C2)  Women 386 284 53       
 BMI  Men 30.0 ± 6.8 30.6 ± 5.4 29.4 ± 5.4 0.20 0.60 -0.004 (0.005) 0.35 -0.008 (0.006) 0.16 
 (kg m-2) Women 27.6 ± 4.7 28.7 ± 6.1 28.5 ± 4.8 0.017 0.0032 -0.012 (0.004) 0.0015 -0.015 (0.005) 0.00090 
 VFA Men 153.8 ± 68.0 161.3 ± 69.3 137.2 ± 54.8 0.072 0.046 0.010 (0.014) 0.48 -0.005 (0.018) 0.77 
 (cm2) Women 93.3 ± 49.3 107.4 ± 58.1 105.8 ± 52.8 0.0015 0.00044 -0.047 (0.014) 0.0011 -0.060 (0.018) 0.0010 
 SFA Men 202.1 ± 107.5 214.3 ± 111.3 199.9 ± 102.5 0.13 0.43 -0.016 (0.013) 0.22 -0.025 (0.017) 0.14 
 (cm2) Women 228.5 ± 84.9 257.4 ± 111.1 253.0 ± 89.0 0.00042 0.00045 -0.033 (0.009) 0.00062 -0.042 (0.012) 0.00048 
Data are shown as the mean ± SD.  Differences in the quantities of anthropometric data among the different genotypes were assessed by the ANCOVA, adjusted with age and/or institute.  Data of additive 
and recessive model were derived from a linear regression analysis.  BMI, VFA, and SFA were adjusted for age and institute after the values of BMI, VFA, and SFA were logarithmically transformed.  
Tested alleles (allele1 at both SNPs) are risk alleles of increased blood pressure. 
Supplementary Table 3  Relationship between rs1004467 and rs11191548, and adiposity in men and women without 147 type 2 diabetic subjects 
SNP ID   Values at each genotype ANCOVA  Additive model Recessive model 
(gene) Phenotype Gender 11 12 22 P-value β (SE) P-value β (SE) P-value 
rs1004467 n Men 205 219 60      
(CYP17A1)  Women 294 273 81      
 BMI  Men 29.6 ± 6.8 30.3 ± 6.0 29.8 ± 4.9 0.21 -0.010 (0.005) 0.055 -0.015 (0.007) 0.028 
 (kg m-2) Women 27.1 ± 4.3 28.3 ± 5.9 28.7 ± 5.1 0.0066 -0.012 (0.004) 0.0032 -0.017 (0.006) 0.0028 
 VFA Men 153.9 ± 68.1 160.2 ± 69.2 139.8 ± 59.1 0.11  0.011 (0.015) 0.45 -0.004 (0.020) 0.83 
 (cm2) Women 88.7 ± 47.4 101.4 ± 54.2 103.6 ± 53.5 0.0030 -0.044 (0.015) 0.0027 -0.064 (0.020) 0.0018 
 SFA Men 199.8 ± 104.0 209.9 ± 116.1 207.9 ± 102.0 0.21 -0.023 (0.014) 0.10 -0.030 (0.019) 0.13 
 (cm2) Women 224.6 ± 79.1 248.9 ± 105.8 273.4 ± 103.8 8.4×10-5 -0.037 (0.010) 0.00013 -0.045 (0.013) 0.00073 
rs11191548 n Men 255 182 47      
(NT5C2)  Women 347 253 48      
 BMI  Men 29.8 ± 7.0 30.1 ± 5.3 29.4 ± 5.4 0.49 -0.006 (0.005) 0.23 -0.011 (0.007) 0.12 
 (kg m-2) Women 27.2 ± 4.4 28.6 ± 6.0 28.2 ± 4.3 0.0038 -0.012 (0.005) 0.0066 -0.018 (0.006) 0.0016 
 VFA Men 153.8 ± 68.3 161.3 ± 69.4 137.2 ± 54.8 0.082  0.009 (0.015) 0.54 -0.006 (0.020) 0.78 
 (cm2) Women 89.7 ± 47.3 103.3 ± 55.7 101.7 ± 52.6 0.0027 -0.043 (0.016) 0.0077 -0.059 (0.020) 0.0037 
 SFA Men 202.5 ± 108.6 210.9 ± 112.3 199.9 ± 102.5 0.26 -0.021 (0.015) 0.16 -0.031 (0.019) 0.11 
 (cm2) Women 225.6 ± 81.7 259.2 ± 110.7 256.0 ± 86.1 6.9×10-5 -0.037 (0.011) 0.00039 -0.052 (0.013) 0.00011 
147 type 2 diabetic patients treated with sulfonylureas, biguanides and thiazolidinediones were excluded.  Data are shown as the mean ± SD.  Differences in the quantities of 
anthropometric data among the different genotypes were assessed by the ANCOVA, adjusted with age.  Data of additive and recessive model were derived from a linear regression 
analysis.  BMI, VFA, and SFA were adjusted for age after the values of BMI, VFA, and SFA were logarithmically transformed.  Tested alleles (allele1 at both SNPs) are risk alleles of 
increased blood pressure. 
Supplementary Table 4  Effect of risk alleles of blood pressure-associated loci on blood pressure and hypertension in this study 
 Nearby Systolic bold pressure Diastolic blood pressure Hypertension 
SNP ID gene β SE P-value β SE P-value OR (95%CI) P-value 
rs16998073 FGF5 2.181 0.810 0.0072 1.041 0.541 0.055 1.10 (0.91 – 1.32) 0.33 
rs11014166 CACNB2 -0.874 1.695 0.61 -1.186 1.130 0.29 0.75 (0.50 – 1.12) 0.16 
rs1530440 C10orf107 -0.253 1.073 0.81 -0.067 0.716 0.93 0.97 (0.76 – 1.25) 0.84 
rs1004467 CYP17A1 1.215 0.788 0.12 0.527 0.526 0.32 1.20 (1.00 – 1.43) 0.053 
rs11191548 NT5C2 1.712 0.837 0.041 0.668 0.559 0.23 1.28 (1.05 – 1.55) 0.013 
rs381815 PLEKHA7 -1.068 0.933 0.25 -0.275 0.623 0.66 0.86 (0.69 – 1.06) 0.15 
rs2681472 ATP2B1 0.771 0.772 0.32 0.251 0.515 0.63 1.12 (0.94 – 1.34) 0.21 
rs2681492 ATP2B1 0.705 0.774 0.36 0.239 0.516 0.64 1.12 (0.94 – 1.34) 0.20 
rs6495112 ARID3B -0.512 0.781 0.51 0.293 0.521 0.57 1.07 (0.89 – 1.27) 0.48 
rs1378942 CSK 1.816 0.942 0.054 0.776 0.629 0.22 1.09 (0.88 – 1.35) 0.43 
rs12946454 PLCD3 -0.885 1.027 0.39 -0.259 0.685 0.71 1.00 (0.79 – 1.26) 1.00 
rs16948048 ZNF652 1.425 1.113 0.20 0.106 0.743 0.89 1.04 (0.80 – 1.34) 0.78 
Data were derived from a linear regression analysis or logistic regression analysis.  Systolic and diastolic blood pressure, and hypertension were adjusted for 
age, age2, gender, and BMI, according to Takeuchi et al.28  In individuals receiving antihypertensive therapies, blood pressure was imputed by adding 
15mmHg and 10mmHg for systolic and diastolic blood pressures, respectively.  Tested alleles are risk alleles of increased blood pressure.  OR, odds ratio; 
CI, confidential interval. 
 
